A Phase 1 Randomized, 2-way, Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2018
At a glance
- Drugs ASP-6981 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Astellas Pharma Global Development
- 31 Aug 2018 Biomarkers information updated
- 15 Jul 2018 Status changed from recruiting to completed.
- 13 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.